{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:26:35Z","timestamp":1774581995501,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000004"],"award-info":[{"award-number":["UL1 TR000004"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T08:46:47Z","timestamp":1433148407000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase"],"prefix":"10.1016","volume":"117","author":[{"given":"Laurie","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Rhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Bavdekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Mardach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hangartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak-Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Crombez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2015.05.012_bb0005","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0015","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0020","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2015.05.012_bb0025","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0040","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2015.05.012_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2052-1839-14-10","article-title":"Long-term effect of imiglucerase in Latin American children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher Registry","volume":"14","author":"Camelo","year":"2014","journal-title":"BMC Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0065","series-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959"},{"key":"10.1016\/j.ymgme.2015.05.012_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/adc.51.3.170","article-title":"Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty","volume":"51","author":"Tanner","year":"1976","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1203\/01.PDR.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: genotype\u2013phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2015.05.012_bb0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.ymgme.2015.05.012_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-3476(96)70203-2","article-title":"Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase","volume":"129","author":"Kaplan","year":"1996","journal-title":"J. Pediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T02:21:58Z","timestamp":1537582918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300172"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.05.012","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Shire Development LLC. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}